View Older Stories View More Recent Stories

Feb 15, 2024 05:29PM Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 9, 2024 04:33PM Form 4 Xilio Therapeutics, Inc. For: Feb 08 Filed by: Atlas Venture Associates XI, LLC
Feb 9, 2024 04:10PM Form SC 13G/A Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 9, 2024 04:08PM Form SC 13G/A Day One Biopharmaceutica Filed by: Atlas Venture Fund XI, L.P.
Feb 9, 2024 04:06PM Form SC 13G/A Generation Bio Co. Filed by: Atlas Venture Fund X, L.P.
Feb 9, 2024 04:04PM Form SC 13G/A Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Feb 9, 2024 04:00PM Form 13F-HR Atlas Venture Life Scien For: Dec 31
Feb 7, 2024 07:00AM Arkuda Therapeutics Announces Option and Asset Purchase Agreement
Feb 2, 2024 10:21AM Form 13F-NT Atlas Venture Associates For: Dec 31
Feb 2, 2024 10:20AM Form 13F-NT Atlas Venture Fund VIII, For: Dec 31
Feb 2, 2024 10:19AM Form 13F-HR Atlas Venture Advisors, For: Dec 31
Feb 2, 2024 10:17AM Form 13F-NT Atlas Venture Associates For: Dec 31
Feb 1, 2024 09:00AM Be Biopharma to Present at the 20th Annual WORLDSymposium™ 2024
Jan 29, 2024 04:47PM Form 144 DraftKings Holdings Inc. Filed by: Atlas Venture Fund VIII, L.P.
Jan 25, 2024 04:39PM Form SC 13D/A Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jan 25, 2024 04:32PM Form 4 Disc Medicine, Inc. For: Jan 23 Filed by: Atlas Venture Opportunity Fund II, L.P.
Jan 25, 2024 09:00AM Be Biopharma to Present at Keystone Symposia on Emerging Cellular Therapies
Jan 23, 2024 05:48PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.
Jan 23, 2024 05:47PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Jan 23, 2024 05:45PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jan 23, 2024 06:00AM Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies
Jan 17, 2024 06:00AM Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia
Jan 16, 2024 06:16PM Form 4 Xilio Therapeutics, Inc. For: Jan 11 Filed by: Atlas Venture Associates XI, LLC
Jan 12, 2024 05:12PM Form 4 Disc Medicine, Inc. For: Jan 10 Filed by: Atlas Venture Associates Opportunity I, L.P.
Jan 10, 2024 09:52PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Jan 10, 2024 09:45PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jan 4, 2024 04:01PM Be Biopharma Expands Leadership Team as Company Transitions to Clinical Stage Organization
Jan 4, 2024 10:00AM Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team
Jan 3, 2024 07:00AM Remix Therapeutics Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease
Dec 28, 2023 09:00AM Be Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 21, 2023 09:00AM Kinaset Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Dec 19, 2023 02:09PM Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors
Dec 14, 2023 08:14PM Form 4 Disc Medicine, Inc. For: Dec 12 Filed by: Atlas Venture Fund X, L.P.
Dec 13, 2023 07:00AM Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors
Dec 12, 2023 06:04PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Dec 12, 2023 06:01PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Dec 12, 2023 08:00AM Aiolos Bio Strengthens and Expands Leadership Team with Key Appointments
Dec 10, 2023 12:30PM Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B​
Dec 7, 2023 09:00AM Kinaset Therapeutics to Present KN-002 Phase 1 Clinical Study Outcomes at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Dec 4, 2023 08:00AM K36 Therapeutics Announces Presentation on KTX-1001 for Relapsed and Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
Nov 22, 2023 09:00AM Be Biopharma to Present at the 35th Annual Piper Sandler Healthcare Conference
Nov 16, 2023 07:06AM Homology Medicines (FIXX) and Q32 Bio to Merge
Nov 16, 2023 07:05AM Q32 Bio and Homology Medicines Announce Merger Agreement
Nov 15, 2023 08:00AM K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer
Nov 13, 2023 04:16PM Form SC 13D Korro Bio, Inc. Filed by: Atlas Venture Fund XI, L.P.
Nov 13, 2023 04:15PM Form 13F-HR Atlas Venture Life Scien For: Sep 30
Nov 13, 2023 10:52AM Form 13F-NT Atlas Venture Fund VIII, For: Sep 30
Nov 13, 2023 10:46AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 13, 2023 10:43AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 13, 2023 10:41AM Form 13F-HR Atlas Venture Associates For: Sep 30
View More Recent Stories View Older Stories